Drug Profile
Dextran sulfate-low molecular weight - TikoMed
Alternative Names: Dextran sulfate sodium; DSSS5; IBsolvMIR; ILB®; LMW-DS; Low molecular weight dextran sulfate; TM-400; TM-500; TM-700Latest Information Update: 03 Nov 2022
Price :
$50
*
At a glance
- Originator TikoMed
- Developer TikoMed; Uppsala University
- Class Anti-inflammatories; Anticoagulants; Antiglaucomas; Antihyperglycaemics; Antihyperlipidaemics; Antivirals; Glucans; Neuroprotectants; Small molecules; Vascular disorder therapies
- Mechanism of Action Blood coagulation factor inhibitors; Complement system protein inhibitors; Immunosuppressants; Intracellular signalling peptide and protein stimulants; Tumour necrosis factor alpha inhibitors; Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Pancreas transplant rejection
Highest Development Phases
- Phase II Amyotrophic lateral sclerosis; Motor neuron disease; Pancreas transplant rejection; Type 1 diabetes mellitus
- Preclinical COVID 2019 infections; Glaucoma; Stroke; Traumatic brain injuries
- No development reported Stem cell mobilisation